Janssen to develop and commercialize Alligator’s immuno-oncology agent ADC-1013
Janssen Biotech has entered into an exclusive, worldwide license agreement with Swedish biotech firm Alligator Bioscience for ADC-1013, an immuno-oncology agent currently being evaluated in Phase I clinical trials.
As part of the deal, Janssen will secure rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody, that targets CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendritic cells.
Stimulating the CD40 receptor initiates a process that leads to an increase in T cells attacking a tumor.
The deal will see Alligator receive an upfront payment plus additional milestone payments contingent upon reaching certain pre-determined development, regulatory and commercial milestones.
Currently, Alligator will complete the existing Phase I dose escalation trial of ADC-1013, while Janssen will be responsible for all subsequent development of this immuno-oncology agent, including research, development, manufacturing, regulatory and commercialization activities.
In a separate deal, Johnson & Johnson Innovation – JJDC will subscribe for new shares of Alligator stock.
Janssen Research & Development Global Oncology head Peter Lebowitz said: “ADC-1013 is a great addition to our growing immuno-oncology portfolio, which includes a broad range of approaches in both solid tumors and hematologic malignancies.
“We were very impressed with the properties of this antibody and we are excited to continue the development that will ultimately deliver it to patients.”
Alligator is focused on developing new antibody-based immunotherapies to treat cancer.